Comparison of Decolonization of Methicillin-resistant Staphylococcus Aureus (MRSA) Using Theraworx - Full Text View

Comparison of Decolonization of Methicillin-resistant Staphylococcus Aureus (MRSA) Using Theraworx (SJMRSA)

This study has been withdrawn prior to recruitment.

( Lack of patient recruitment. )

First Received: July 7, 2008 Last Updated: January 11, 2010 History of Changes

Sponsor:	St. John's Health System, Missouri
Information provided by:	St. John's Health System, Missouri
ClinicalTrials.gov Identifier:	NCT00713674

Purpose

The purpose of this study is to examine treatment method of Methicillin-resistant Staphylococcus aureus (MRSA) decolonization in patients.

Condition	Intervention
Methicillin-resistant Staphylococcus Aureus	Other: Theraworx Drug: mupirocin antibiotic ointment

Study Type:	Interventional
Study Design:	Treatment, Randomized, Single Blind (Subject), Parallel Assignment, Safety/Efficacy Study
Official Title:	Comparison of Decolonization of MRSA Using Theraworx

Resource links provided by NLM:

MedlinePlus related topics: Antibiotics

Drug Information available for: Methicillin Mupirocin Mupirocin calcium Methicillin sodium

U.S. FDA Resources

Further study details as provided by St. John's Health System, Missouri:

Primary Outcome Measures:

Evidence of decolonization confirmed by intranasal culture [ Time Frame: Up to 14 days post treatment (+/- 1-2 days) ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:

Economic-Cost comparison of treatment Evidence of decolonization [ Time Frame: 5 days of treatment ] [ Designated as safety issue: Yes ]

Estimated Enrollment:	60
Study Start Date:	March 2008
Estimated Study Completion Date:	February 2009
Primary Completion Date:	February 2009 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
1: No Intervention No Treatment
2: Experimental Theraworx intranasal	Other: Theraworx Theraworx swab intranasal BID for 5 days
3: Active Comparator mupirocin antibiotic ointment intranasal	Drug: mupirocin antibiotic ointment mupirocin antibiotic ointment swab intranasal BID for 5 days

Detailed Description:

Decolonization therapy is indicated for management of patients with MRSA. Theraworx is reported to be an effective antimicrobial against multiple organisms. In this study, patients with positive MRSA colonization culture will be treated with Theraworx to evaluate decolonization duration capability.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Positive MRSA culture

Exclusion Criteria:

Patients currently on or start antibiotic therapy directed for MRSA.(Prophylaxis antibiotic for surgical procedure not considered therapy.)
Patients with MRSA infected wounds
Patients under the age of 18 years
A woman currently pregnant or nursing a child
Patients participating in another study within 30 days of randomization

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00713674

Locations

United States, Missouri
St John's Hospital-Medical Research Institute
Springfield, Missouri, United States, 65804

Sponsors and Collaborators

St. John's Health System, Missouri

Investigators

Principal Investigator:

Roger E Huckfeldt, MD

St. Johns' Health System-Medical Research Institute

More Information

No publications provided

Responsible Party:	St. John's Medical Research Institute ( Roger Huckfeldt, MD )
Study ID Numbers:	SJMRSA-01
Study First Received:	July 7, 2008
Last Updated:	January 11, 2010
ClinicalTrials.gov Identifier:	NCT00713674 History of Changes
Health Authority:	United States: Institutional Review Board

Keywords provided by St. John's Health System, Missouri:

Methicillin resistance

Additional relevant MeSH terms:

Bacterial Infections
Protein Synthesis Inhibitors
Anti-Infective Agents
Anti-Bacterial Agents
Staphylococcal Infections
Gram-Positive Bacterial Infections

Mupirocin
Methicillin
Molecular Mechanisms of Pharmacological Action
Therapeutic Uses
Enzyme Inhibitors
Pharmacologic Actions

ClinicalTrials.gov processed this record on February 08, 2010